JP2020511473A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020511473A5 JP2020511473A5 JP2019551284A JP2019551284A JP2020511473A5 JP 2020511473 A5 JP2020511473 A5 JP 2020511473A5 JP 2019551284 A JP2019551284 A JP 2019551284A JP 2019551284 A JP2019551284 A JP 2019551284A JP 2020511473 A5 JP2020511473 A5 JP 2020511473A5
- Authority
- JP
- Japan
- Prior art keywords
- epilepsy
- composition according
- seizures
- syndrome
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762471635P | 2017-03-15 | 2017-03-15 | |
| US62/471,635 | 2017-03-15 | ||
| US201762608207P | 2017-12-20 | 2017-12-20 | |
| US62/608,207 | 2017-12-20 | ||
| US201862635871P | 2018-02-27 | 2018-02-27 | |
| US62/635,871 | 2018-02-27 | ||
| PCT/US2018/022573 WO2018170223A1 (en) | 2017-03-15 | 2018-03-15 | Use of designer receptors exclusively activated by designer drugs in the treatment of seizure disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020511473A JP2020511473A (ja) | 2020-04-16 |
| JP2020511473A5 true JP2020511473A5 (https=) | 2021-04-22 |
Family
ID=63523332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019551284A Pending JP2020511473A (ja) | 2017-03-15 | 2018-03-15 | 発作性疾患の治療におけるデザイナー化合物によりのみ活性化するデザイナー受容体の使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20190060400A1 (https=) |
| EP (1) | EP3595669A4 (https=) |
| JP (1) | JP2020511473A (https=) |
| KR (1) | KR20190124309A (https=) |
| CN (1) | CN110621318A (https=) |
| AU (1) | AU2018234644A1 (https=) |
| BR (1) | BR112019019078A2 (https=) |
| CA (1) | CA3056410A1 (https=) |
| IL (1) | IL269310A (https=) |
| MX (1) | MX2019010982A (https=) |
| WO (1) | WO2018170223A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020002148A (es) * | 2017-08-25 | 2020-07-20 | Ovid Therapeutics Inc | Vectores adenoasociados recombinantes. |
| CA3084985A1 (en) | 2017-12-06 | 2019-06-13 | Ovid Therapeutics Inc. | Use of mir101 or mir128 in the treatment of seizure disorders |
| WO2019113538A2 (en) * | 2017-12-07 | 2019-06-13 | California Institute Of Technology | Methods and systems for noninvasive control of brain cells and related vectors and compositions |
| CN111867595A (zh) * | 2017-12-20 | 2020-10-30 | 奥维德医疗公司 | hM4Di在治疗癫痫发作紊乱中的用途 |
| US11123332B2 (en) | 2018-11-21 | 2021-09-21 | Certego Therapeutics Inc. | Gaboxadol for reducing risk of suicide and rapid relief of depression |
| MX2022009982A (es) * | 2020-02-14 | 2022-09-12 | Ultragenyx Pharmaceutical Inc | Terapia genica para el tratamiento de transtorno por deficiencia de cdkl5. |
| MX2022014599A (es) | 2020-05-20 | 2022-12-16 | Certego Therapeutics Inc | Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos. |
| KR102878106B1 (ko) * | 2021-12-24 | 2025-10-28 | 서울대학교산학협력단 | 신경수초 가소성 증진 방법 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003221733A1 (en) * | 2002-04-17 | 2003-11-03 | University Of Florida Research Foundation, Inc. | Improved raav vectors |
| GB201404470D0 (en) * | 2014-03-13 | 2014-04-30 | Ucl Business Plc | Therapeutic methods and materials |
-
2018
- 2018-03-15 CA CA3056410A patent/CA3056410A1/en active Pending
- 2018-03-15 WO PCT/US2018/022573 patent/WO2018170223A1/en not_active Ceased
- 2018-03-15 MX MX2019010982A patent/MX2019010982A/es unknown
- 2018-03-15 CN CN201880030980.6A patent/CN110621318A/zh active Pending
- 2018-03-15 EP EP18768245.5A patent/EP3595669A4/en not_active Withdrawn
- 2018-03-15 US US15/921,906 patent/US20190060400A1/en not_active Abandoned
- 2018-03-15 BR BR112019019078A patent/BR112019019078A2/pt not_active IP Right Cessation
- 2018-03-15 AU AU2018234644A patent/AU2018234644A1/en not_active Abandoned
- 2018-03-15 KR KR1020197030149A patent/KR20190124309A/ko not_active Withdrawn
- 2018-03-15 JP JP2019551284A patent/JP2020511473A/ja active Pending
-
2019
- 2019-09-12 IL IL26931019A patent/IL269310A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020511473A5 (https=) | ||
| US20230263910A1 (en) | Aav vectors targeted to the central nervous system | |
| US12076351B2 (en) | AAV vectors targeted to oligodendrocytes | |
| JP2019089787A5 (https=) | ||
| CN106488984B (zh) | 一种治疗周围神经病变以及运动神经元疾病的方法 | |
| IL273261B1 (en) | Adeno-associated virus variant capsids and methods of use thereof | |
| JP2017533715A5 (https=) | ||
| Reid et al. | miRNA-mediated post-transcriptional silencing of transgenes leads to increased adeno-associated viral vector yield and targeting specificity | |
| JP2019519218A5 (https=) | ||
| JP2019513393A5 (https=) | ||
| CN107893078B (zh) | 靶向突触结合蛋白-11的siRNA、表达载体和病毒颗粒及其制药应用 | |
| TW201629225A (zh) | 第九因子基因療法 | |
| US20220380807A1 (en) | Method for reducing the expression of nkcc1 in a subject | |
| JP2017506230A5 (https=) | ||
| EP4045653A1 (en) | Gene therapy for alzheimer's disease | |
| JP2021505619A5 (https=) | ||
| CN112029773B (zh) | 编码bdnf的核酸及其应用 | |
| US20230313223A1 (en) | Methods for modulating level of expression from gene therapy expression cassette | |
| CN114126667A (zh) | 使用糖苷水解酶的基因疗法载体向视网膜细胞的改进递送 | |
| JP2018509912A5 (https=) | ||
| EP4689120A2 (en) | Compositions and methods for treating cag repeat diseases | |
| Cagin | Targeting age-related neurodegenerative diseases by AAV-Mediated gene therapy | |
| Arora et al. | Gene therapies for neurodegenerative disease: current knowledge and challenges | |
| WO2022226294A1 (en) | Chimeric aav5 capsids | |
| WO2025164317A1 (ja) | 改良型ミクログリア標的ａａｖベクター |